Abstract
This chapter explores immunotherapy use for the treatment of metastatic urothelial cancer. Anti-PD-1 and PD-L1 agents such as atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab are reviewed. These agents show great promise in the treatment of metastatic urothelial cancer with manageable toxicity profiles when compared to chemotherapy. All of these agents are approved for treating metastatic urothelial cancer in the second-line setting, while atezolizumab and pembrolizumab are approved for treatment in the first-line setting. Trials in other disease states are ongoing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
